Company / SG&A Expense
Harmony Biosciences Holdings, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$152.5M
FY2025
5-year range
$36.4M / $152.5M
FY2021-FY2025
Trend
+38.2%
vs FY2024
Sector context
#91 of 213
Health Care
What the data says
At $153M, Harmony Biosciences Holdings, Inc.'s sg&a expense ranks #123 of 213 in the Health Care sector. SG&A Expense has increased for 4 consecutive years, from $36M in FY2021 to $153M in FY2025.
Based on SEC 10-K filings.
$153M in FY2025 with a 5-year CAGR of +33.2%.
Increased from $95M to $153M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +22.0%
- 5-Year CAGR
- +33.2%
- 10-Year CAGR
- -
Sector benchmark
#123 of 213 in Health CareTop 57% of 213This company $152.5M Sector average $722.3M
▼
-78.9% below sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +33.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 38.2% year-over-year.
- Ranks #91 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $152.5M | +38.2% |
| FY2024 | $110.4M | +15.8% |
| FY2023 | $95.3M | +13.4% |
| FY2022 | $84.0M | +130.8% |
| FY2021 | $36.4M | +0.0% |
| FY2020 | $36.4M | +0.0% |
| FY2019 | $36.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026